| Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer F Crea, A Watahiki, L Quagliata, H Xue, L Pikor, A Parolia, Y Wang, D Lin, ... Oncotarget 5 (3), 764, 2014 | 236 | 2014 |
| Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer F Crea, EM Hurt, LA Mathews, SM Cabarcas, L Sun, VE Marquez, ... Molecular cancer 10, 1-10, 2011 | 202 | 2011 |
| EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis F Crea, L Fornaro, G Bocci, L Sun, WL Farrar, A Falcone, R Danesi Cancer and Metastasis Reviews 31, 753-761, 2012 | 178 | 2012 |
| Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies F Crea, S Nobili, E Paolicchi, G Perrone, C Napoli, I Landini, R Danesi, ... Drug Resistance Updates 14 (6), 280-296, 2011 | 156 | 2011 |
| Polycomb-mediated silencing in neuroendocrine prostate cancer PL Clermont, D Lin, F Crea, R Wu, H Xue, Y Wang, KL Thu, WL Lam, ... Clinical epigenetics 7, 1-13, 2015 | 142 | 2015 |
| Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer A Watahiki, RJ Macfarlane, ME Gleave, F Crea, Y Wang, CD Helgason, ... International journal of molecular sciences 14 (4), 7757-7770, 2013 | 140 | 2013 |
| Long non-coding RNAs in the doxorubicin resistance of cancer cells S Ashrafizaveh, M Ashrafizadeh, A Zarrabi, K Husmandi, A Zabolian, ... Cancer Letters 508, 104-114, 2021 | 133 | 2021 |
| Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells A Avan, F Crea, E Paolicchi, N Funel, E Galvani, VE Marquez, ... Molecular cancer therapeutics 11 (8), 1735-1746, 2012 | 122 | 2012 |
| The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer F Crea, E Venalainen, X Ci, H Cheng, L Pikor, A Parolia, H Xue, ... Epigenomics 8 (5), 721-731, 2016 | 116 | 2016 |
| The non-coding transcriptome as a dynamic regulator of cancer metastasis F Crea, PL Clermont, A Parolia, Y Wang, CD Helgason Cancer and metastasis reviews 33, 1-16, 2014 | 103 | 2014 |
| BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer F Crea, MA Duhagon Serrat, EM Hurt, SB Thomas, R Danesi, WL Farrar International journal of cancer 128 (8), 1946-1954, 2011 | 103 | 2011 |
| The long and short non-coding RNAs modulating EZH2 signaling in cancer S Mirzaei, MH Gholami, K Hushmandi, F Hashemi, A Zabolian, I Canadas, ... Journal of hematology & oncology 15 (1), 18, 2022 | 102 | 2022 |
| Polycomb genes and cancer: time for clinical application? F Crea, E Paolicchi, VE Marquez, R Danesi Critical reviews in oncology/hematology 83 (2), 184-193, 2012 | 101 | 2012 |
| The emerging role of histone lysine demethylases in prostate cancer F Crea, L Sun, A Mai, YT Chiang, WL Farrar, R Danesi, CD Helgason Molecular cancer 11, 1-10, 2012 | 99 | 2012 |
| Clinical significance of Polycomb gene expression in brain tumors F Crea, EM Hurt, WL Farrar Molecular cancer 9, 1-6, 2010 | 99 | 2010 |
| Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role PL Clermont, L Sun, F Crea, KL Thu, A Zhang, A Parolia, WL Lam, ... British journal of cancer 111 (8), 1663-1672, 2014 | 94 | 2014 |
| Epigenetic gene regulation in stem cells and correlation to cancer LA Mathews, F Crea, WL Farrar Differentiation 78 (1), 1-17, 2009 | 92 | 2009 |
| The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo A Parolia, F Crea, H Xue, Y Wang, F Mo, VR Ramnarine, HH Liu, D Lin, ... Molecular cancer 14, 1-7, 2015 | 90 | 2015 |
| Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response M Ashrafizadeh, MDA Paskeh, S Mirzaei, MH Gholami, A Zarrabi, ... Journal of Experimental & Clinical Cancer Research 41 (1), 105, 2022 | 85 | 2022 |
| Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer PL Clermont, F Crea, YT Chiang, D Lin, A Zhang, JZL Wang, A Parolia, ... Clinical epigenetics 8, 1-14, 2016 | 83 | 2016 |
Yuzhuo Wang, Ph.D. FCAHSProfessor of Urologic Sciences, UBCVerified email at bccrc.ca
